Tissue Therapies
HOME TECHNOLOGY INVESTORS ALLIANCES COMPANY
CONTACT

COMPANY

BACKGROUND

THE TEAM

THE BOARD

 - ROGER CLARKE

- STEVEN MERCER

- GREG BAYNTON

- MEL BRIDGES

- DR CHERRELL HIRST

- ROBERT BAXTER

- KEITH HARDING

- DRUMMOND McKENZIE
HOME COMPANY BOARD OF DIRECTORS   
BOARD OF DIRECTORS ::

CHAIRMAN: ROGER CLARKE
Mr Roger Clarke has over 30 years commercial experience, principally in the investment banking industry.

EXECUTIVE DIRECTOR: STEVEN MERCER
Dr Mercer brings considerable international expertise to Tissue Therapies following a successful career with multinational companies.

NON-EXECUTIVE DIRECTOR: GREG BAYNTON
Mr Greg Baynton is Managing Director of Orbit Capital, a private investment bank and holder of an Australian Financial Services Licence.


NON-EXECUTIVE DIRECTOR: MEL BRIDGES
Past & present Chairman & Director of multiple listed and private biotech companies including Arana Therapeutics, Alchemia and ImpediMed.


NON-EXECUTIVE DIRECTOR: DR CHERRELL HIRST AO
Past and present Chair and Director of multiple biotech companies including Peplin, ImpediMed and QBF.


SCIENTIFIC ADVISOR TO THE BOARD: PROFESSOR ROBERT BAXTER
Professor Robert Baxter is a leading expert in proteins that regulate cell growth and metabolism, the insulin-like growth factors and their binding proteins.


CLINICAL ADVISOR TO THE BOARD: KEITH HARDING
Professor Harding is recognised as one of the leading expert wound care researchers and clinicians in the world today.


COMPANY SECRETARY: DRUMMOND McKENZIE
Mr Drummond McKenzie is a Chartered Accountant and is the Chief Finance Officer and Company Secretary of an Australian insurance company.





© 2007 TISSUE THERAPIES LTD